| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919127 | Radiotherapy and Oncology | 2013 | 5 Pages |
Abstract
These results suggest that short SBRT with cetuximab is an effective salvage treatment with good response rate in this poor prognosis population with previously irradiated HNC. Treatment is feasible and, with appropriate care to limiting critical structure, acute toxicities are acceptable. This combination may be the reference treatment is this population.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Eric F. Lartigau, Emmanuelle Tresch, Juliette Thariat, Pierre Graff, Bernard Coche-Dequeant, Karen Benezery, Luis Schiappacasse, Marian Degardin, Pierre-Yves Bondiau, Didier Peiffert, Jean-Louis Lefebvre, Thomas Lacornerie, Andrew Kramar,